Shire scoops up Advanced BioHealing ahead of IPO
This article was originally published in Scrip
Executive Summary
Shire has swooped in to acquire Advanced BioHealing for $750 million in cash. The US regenerative medicine firm filed for an IPO worth up to $225 million having priced 13.35 million shares at between $14 and $16 each just a week ago. This implied a post-money valuation of around $560-640 million. Shire's bid thus represents a premium to the pre-money valuation of around 50-70%.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.